News

The trial is evaluating OPGx-MERTK gene therapy for MERTK-related retinitis pigmentosa (RP).

The trial will evaluate the safety and effectiveness of the company's titratable glaucoma therapy system, designed to optimize IOP reduction in patients undergoing glaucoma surgery.

According to the company, this meeting helped to provide a “clear path forward” for CBT-004 in its projected phase 3 study

This enables the initiation of the EYETAC phase II clinical trial (NCT07285070) in patients with non-infectious anterior uveitis (NIAU).

From artificial intelligence and IOL innovation to biosimilars, geographic atrophy, and postoperative eye protection, Joshua Mali, MD, FASRS, shares what he believes will define ophthalmology in the year ahead.

A study reveals that low-dose pilocarpine effectively reduces pupil size in presbyopic eyes with minimal impact on lens thickness and accommodation.

The January 31, 2026, conference in Mainz, Germany, will focus on advances in optic neuropathy diagnosis, artificial intelligence applications, and surgical perspectives

FDA authorizes compassionate use of urcosimod for neuropathic corneal pain, a condition that causes severe pain and sensitivity of the eyes, face, or head.

James Tsai, MD, MBA, sheds light on what is in the offing for glaucoma specialists

James Tsai, MD, MBA, discusses his approaches given the wide diversity of patients in a major urban setting when awareness of glaucoma can range from highly educated patients to uninformed individuals.

Data estimates the prevalence of glaucoma currently is almost 50% higher than previously estimated and over 1.6 million individuals in the UK are estimated to have glaucoma by 2060.

The Bimatoprost Drug Pad-IOL System is intended for the lowering of intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension (OHT).

Analysis of 20 years of data highlights differences in reimbursement trends across ophthalmology subspecialties and practice settings, according to Dustin D. French, PhD.

Broadwood and Yunqi Capital will add 3 total members to the board, while the CEO and more step down.

A total of 38 patients were included in the study. All underwent implantation of the PRIMAretinal prosthetic chip with the goal of restoring vision.

The trial is evaluating OCU410 (AAV5-RORA) for the treatment of geographic atrophy (GA) secondary to dry age-related macular degeneration.

Key clinical trial data and PDUFA dates in early 2026 focus on treatments for dry eye, AMD, and rare eye diseases.

The Swiss-designed phaco platform provides mobility, simplified workflows, and reduced surgical waste for cataract procedures, according to the company.

OCU410ST uses an adeno-associated virus delivery platform for the retinal delivery of the RORA gene.

Formerly, the EDOF technology was specifically limited to intraocular lenses.

Patients underwent a full ophthalmologic examination that included optical coherence tomography (OCT), OCT angiography, and biometry.

The Investigational New Drug (IND) application from Complement Therapeutics for CTx001 was previously approved by the FDA in October 2025